#59036 Store at -20C

# OX40L (D6K7R) Rabbit mAb

Cell Signaling TECHNOLOGY®

**Orders:** 877-616-CELL (2355) orders@cellsignal.com

**Support:** 877-678-TECH (8324)

**Web:** info@cellsignal.com cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

**For Research Use Only. Not for Use in Diagnostic Procedures.**

| Applications: | Reactivity: | Sensitivity: | Source/Isotype: | UniProt ID: | Entrez-Gene Id: |
|---|---|---|---|---|---|
| IHC-Bond, IHC-P | H | Endogenous | Rabbit IgG | #P23510 | 7292 |

## Product Usage Information

| Application | Dilution |
|---|---|
| IHC Leica Bond | 1:200 |
| Immunohistochemistry (Paraffin) | 1:200 |

## Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

For a carrier free (BSA and azide free) version of this product see product #51635.

## Specificity / Sensitivity

OX40L (D6K7R) Rabbit mAb recognizes endogenous levels of total OX40L protein. Staining of unknown specificity has been observed in skeletal muscle.

## Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala15 of human OX40L protein.

## Background

OX40 (TNFRSF4, CD134) is a member of the tumor necrosis factor (TNF) receptor superfamily that regulates T cell activity and immune responses. The OX40 protein contains four cysteine rich domains, a transmembrane domain, and a cytoplasmic tail containing a QEE motif (1,2). OX40 is primarily expressed on activated CD4+ and CD8+ T-cells, while the OX40 ligand (OX40L, TNFSF4, CD252) is predominantly expressed on activated antigen presenting cells (3-7). The engagement of OX40 with OX40L leads to the recruitment of TNF receptor-associated factors (TRAFs) and results in the formation of a TCR-independent signaling complex. One component of this complex, PKCθ, activates the NF-κB pathway (2,8). OX40 signaling through Akt can also enhance TCR signaling directly (9). Research studies indicate that the OX40L-OX40 pathway is associated with inflammation and autoimmune diseases (10). Additional research studies show that OX40 agonists augment anti-tumor immunity in several cancer types (11,12).

## Background References

1. Croft, M. (2010) *Annu Rev Immunol* 28, 57-78.
2. So, T. and Croft, M. (2012) *Front Immunol* 3, 133.
3. Paterson, D.J. et al. (1987) *Mol Immunol* 24, 1281-90.
4. Mallett, S. et al. (1990) *EMBO J* 9, 1063-8.
5. Dürkop, H. et al. (1995) *Br J Haematol* 91, 927-31.
6. Godfrey, W.R. et al. (1994) *J Exp Med* 180, 757-62.
7. Al-Shamkhani, A. et al. (1997) *J Biol Chem* 272, 5275-82.
8. So, T. et al. (2011) *Proc Natl Acad Sci U S A* 108, 2903-8.
9. So, T. and Croft, M. (2013) *Front Immunol* 4, 139.
10. Gough, M.J. and Weinberg, A.D. (2009) *Adv Exp Med Biol* 647, 94-107.
11. Weinberg, A.D. et al. (2011) *Immunol Rev* 244, 218-31.
12. Linch, S.N. et al. (2015) *Front Oncol* 5, 34.

## Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

## Applications Key

**IHC-Bond:** IHC Leica Bond **IHC-P:** Immunohistochemistry (Paraffin)

## Cross-Reactivity Key

**H:** human **M:** mouse **R:** rat **Hm:** hamster **Mk:** monkey **Vir:** virus **Mi:** mink **C:** chicken **Dm:** D. melanogaster
**X:** Xenopus **Z:** zebrafish **B:** bovine **Dg:** dog **Pg:** pig **Sc:** S. cerevisiae **Ce:** C. elegans **Hr:** horse
**GP:** Guinea Pig **Rab:** rabbit **All:** all species expected

## Trademarks and Patents



## Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.